July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Treatment of Pyogenic Granulomas with Intralesional Injections of Bevacizumab
Author Affiliations & Notes
  • Randal Pham
    Advanced Surgery Medical Center, San Jose, California, United States
    Aesthetic and Refractive Surgery Medical Center, San Jose, California, United States
  • Nancy Phu
    Burrell College of Osteopathic Medicine, Las Cruces, New Mexico, United States
  • Aarin Pham
    Aesthetic and Refractive Surgery Medical Center, San Jose, California, United States
    Byers Eye Institute , Palo Alto, California, United States
  • Clement Chow
    Retinal Diagnostic Center, Campbell, California, United States
  • Footnotes
    Commercial Relationships   Randal Pham, None; Nancy Phu, None; Aarin Pham, None; Clement Chow, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 6250. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Randal Pham, Nancy Phu, Aarin Pham, Clement Chow; Treatment of Pyogenic Granulomas with Intralesional Injections of Bevacizumab. Invest. Ophthalmol. Vis. Sci. 2019;60(9):6250. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report the safety and efficacy of adjuvant bevacizumab in the treatment of ocular pyogenic granuloma manifestation after pterygiectomy.

Methods : We present 2 eyes with formations of pyogenic granulomas after undergoing combined pterygiectomies and amniotic membrane graftings. Intralesional triamcinolone injections did not show sign of regression. Additional injections of bevacizumab were performed.

Results : Within a month of intralesional injections with bevacizumab, the vascular lesions showed complete resolution with no adverse effect.

Conclusions : Intralesional bevacizumab injection is a safe and effective adjuvant therapy in the treatment of post-pterygiectomy conjunctival pyogenic granuloma refractory to steroid therapy.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Figure 1. (A) Color photo showing a 4.2 mm pterygium located nasally in the right eye prior to combined pterygiectomy and amniotic membrane graft surgery. (B) Color photo illustrating vascular lesion growth 2 month post-pterygiectomy. The patient received a 0.03ml triamcinolone injection (40mg/ml). (C) Slit lamp examination of vascular lesion, 1 week post-triamcinolone injection. The vascular lesion appears to be less red. No signs of the growth regressing. The patient received bevacizumab injection (1.25mg/0.05ml). (D) 1 day post bevacizumab injection. The lesion size significantly reduced. (E) Slip lamp examination of lesion, 1 week post-bevacizumab injection. Tissue growth is less erythematous. (F) Slit lamp examination of lesion, 3 week post-bevacizumab injection. Pyogenic granuloma lesion resolved with no hyperemia.

Figure 1. (A) Color photo showing a 4.2 mm pterygium located nasally in the right eye prior to combined pterygiectomy and amniotic membrane graft surgery. (B) Color photo illustrating vascular lesion growth 2 month post-pterygiectomy. The patient received a 0.03ml triamcinolone injection (40mg/ml). (C) Slit lamp examination of vascular lesion, 1 week post-triamcinolone injection. The vascular lesion appears to be less red. No signs of the growth regressing. The patient received bevacizumab injection (1.25mg/0.05ml). (D) 1 day post bevacizumab injection. The lesion size significantly reduced. (E) Slip lamp examination of lesion, 1 week post-bevacizumab injection. Tissue growth is less erythematous. (F) Slit lamp examination of lesion, 3 week post-bevacizumab injection. Pyogenic granuloma lesion resolved with no hyperemia.

 

Figure 2. Examination of appearance of the pyogenic granuloma with one intralesional bevacizumab injection in the right eye, post-op 1 day (left) and 2 week (right).

Figure 2. Examination of appearance of the pyogenic granuloma with one intralesional bevacizumab injection in the right eye, post-op 1 day (left) and 2 week (right).

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×